Clinical Trial Update: Ensartinib After Chemoradiotherapy in Stage III ALK-Mutated NSCLC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating ensartinib after chemoradiotherapy in patients with stage III ALK-mutated non-small cell lung cancer; the trial status is not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Ensartinib (Ensartinib)

Snippet

Sponsor: Shanghai Pulmonary Hospital, Shanghai, China | Conditions: NSCLC Stage III, Ensartinib | Phase 2 | Status: NOT_YET_RECRUITING